Table 1.
Clinical Characteristics of Patients With and Without Primary End Points
| Variables | Overall (n=4003) | Events (n=315) | Nonevents (n=3688) |
|---|---|---|---|
| Age, y | 56.8±10.5 | 61.6±9.4 | 56.6±10.5 |
| Male, n (%) | 3059 (76.4) | 216 (69.5) | 2843 (77.1) |
| BMI, kg/m2 | 26.02±3.18 | 25.90±3.24 | 26.03±3.18 |
| Hypertension, n (%) | 2525 (63.1) | 242 (76.8) | 2283 (61.9) |
| Diabetes mellitus, n (%) | 1141 (28.5) | 105 (33.5) | 1036 (28.1) |
| Current smokers, n (%) | 2160 (54.0) | 195 (61.9) | 1965 (53.3) |
| Alcohol consumption, n (%) | 976 (24.4) | 51 (16.3) | 925 (25.1) |
| Prior myocardial infarction, n (%) | 1281 (32.0) | 101 (32.0) | 1180 (32.0) |
| Prior percutaneous coronary intervention, n (%) | 957 (23.9) | 90 (28.6) | 867 (23.6) |
| Prior Coronary artery bypass grafting, n (%) | 85 (2.0) | 11 (3.4) | 74 (2.0) |
| Prior stroke, n (%) | 134 (3.3) | 27 (8.6) | 107 (2.9) |
| Family history of coronary artery disease, n (%) | 568 (14.2) | 33 (10.6) | 535 (14.5) |
| Systolic blood pressure, mm Hg | 127±17 | 129±18 | 127±17 |
| Diastolic blood pressure, mm Hg | 78±11 | 78±11 | 78±11 |
| Left ventricular ejection fraction, % | 63.8±7.2 | 63.3±7.0 | 63.9±7.2 |
| Total bilirubin, umol/L | 14.72±5.80 | 14.63±5.00 | 14.72±5.84 |
| Albumin, g/dL | 4.37±0.47 | 4.19±0.39 | 4.38±0.48 |
| ALT, IU/L | 25 (18–38) | 22 (16–30) | 25 (18–38) |
| AST, IU/L | 19 (16–24) | 19 (15–25) | 19 (16–24) |
| Gamma‐glutamyltransferase, IU/L | 30 (21–46) | 28 (20–42) | 30 (21‐46) |
| Fasting plasma glucose, mmol/L | 5.90±1.77 | 5.99±1.73 | 5.90±1.77 |
| Glycosylated hemoglobin, % | 6.35±1.13 | 6.58±1.13 | 6.34±1.14 |
| Total cholesterol, mmol/L | 4.10±1.09 | 4.08±1.12 | 4.10±1.11 |
| High‐density lipoprotein cholesterol, mmol/L | 1.04±0.29 | 1.05±0.30 | 1.04±0.29 |
| Low‐density lipoprotein cholesterol, mmol/L | 2.48±0.94 | 2.43±0.88 | 2.49±0.96 |
| Triglycerides, mmol/L | 1.51 (1.14–2.13) | 1.56 (1.05–2.29) | 1.51 (1.14–2.12) |
| Creatinine, umol/L | 78.56±17.36 | 80.89±19.45 | 78.45±17.25 |
| Platelet, 109/L | 212±59 | 204±52 | 213±59 |
| High‐sensitivity C‐reactive protein, mg/L | 1.46 (0.79–2.97) | 1.81 (0.97–3.90) | 1.44 (0.78–2.96) |
| Nonalcoholic fatty liver disease fibrosis score | −1.53(−2.43–[−0.72]) | −0.91(−1.63–[−0.07]) | −1.57(−2.44–[−0.75]) |
| Fibrosis‐4 | 1.06 (0.78–1.44) | 1.28 (0.93–1.66) | 1.05 (0.77–1.43) |
| BMI, AST/ALT ratio, diabetes mellitus score | 1 (0–2) | 2 (0–2) | 1 (0–2) |
| AST/ALT ratio | 0.75 (0.57–1.00) | 0.86 (0.63–1.05) | 0.74 (0.57–0.96) |
| Forns score | 5.63 (5.09–6.14) | 5.80 (5.26–6.31) | 5.62 (5.08–6.13) |
| Gamma‐glutamyltransferase platelet ratio | 0.15 (0.10–0.23) | 0.14 (0.10–0.21) | 0.15 (0.10–0.23) |
| AST to platelet ratio index | 0.27 (0.20–0.36) | 0.86 (0.63–1.05) | 0.27 (0.20–0.36) |
| HUI | 0.14 (0.06–0.31) | 0.20 (0.10–0.38) | 0.14 (0.06–0.31) |
| Baseline medications | |||
| Aspirin, n (%) | 3442 (86.0) | 267 (84.9) | 3175 (86.1) |
| ACEI/ARB, n (%) | 852 (21.3) | 48 (15.2) | 804 (21.8) |
| β‐blockers, n (%) | 2011 (50.2) | 167 (53.0) | 1844 (50.0) |
| CCB, n (%) | 785 (19.6) | 62 (19.7) | 723 (19.6) |
| Statins, n (%) | 2718 (67.9) | 184 (58.5) | 2534 (68.7) |
| Medications at follow‐up | |||
| Aspirin, n (%) | 3986 (99.6) | 313 (99.4) | 3673 (99.6) |
| ACEI/ARB, n (%) | 1966 (49.1) | 178 (56.6) | 1788 (48.5) |
| β‐blockers, n (%) | 3244 (81.0) | 246 (78.1) | 2998 (81.3) |
| CCB, n (%) | 1489 (37.2) | 121 (38.4) | 1368 (37.1) |
| Statins, n (%) | 3760 (93.9) | 293 (93.2) | 3467 (94.0) |
Continuous values are summarized as mean±SD, median (interquartile range) and categorical variables as number (percentage).
ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; BMI, body mass index; and CCB, calcium channel blockers.